

Publications for Paroxetine Clinical Studies In Children And Adolescents

- Alacqua M, Trifiro G, Arcoraci V, et al. Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting. *Pharm World Sci* 2008;30(1):44-50.
- Apter A, Lipschitz A, Fong R, et al. Evaluation of suicidal thoughts and behaviors in children and adolescents taking paroxetine. *J Child Adolesc Psychopharmacol* 2006;16:77-90. (Studies 329/377/676/701/704).
- Bailly D. Benefits and risks of using antidepressants in children and adolescents. *Expert Opin Drug Saf* 2008;7(1):9-27.
- Berard R, Fong R, Carpenter DJ, Thomason C, Wilkinson C. An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. *J Child Adolesc Psychopharmacol* 2006;16:59-75. (Study 377).
- Berard R, Ryan N. Adolescent depression: efficacy of paroxetine. Poster presented at the European College of Neuropsychopharmacology (ECNP) Annual Meeting, Paris, France, October, 1998. (Study 329).
- Berard R, Wagner KD, Carpenter DJ, et al. SSRI therapy for pediatric patients with social anxiety disorder or OCD [abstract]. Poster presented at the American Psychiatric Association (APA) Annual Meeting, San Francisco, CA, May 17-22, 2003, Abstract No.NR702. (Studies 704/676).
- Birmaher B, McCafferty JP, Bellew KM, et al. Comorbid ADHD and disruptive behavior disorders as predictors of response in adolescents treated for major depression [abstract]. Poster presented at the American Psychiatric Association (APA) Annual Meeting, Chicago, IL, May 13-18, 2000, Abstract No.NR562:209. (Study 329).
- Boylan K, Romero S, Birmaher B. Psychopharmacologic treatment of pediatric major depressive disorder. *Psychopharmacology* 2007;191(1):27-38.
- Braconnier A, Le Coent R, Cohen D. Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial. *J Am Acad Child Adolesc Psychiatry* 2003;42:22-29. (Study 511).
- Carpenter DJ, Emslie GJ, Wagner KD, et al. Safety and efficacy of paroxetine in the treatment of children and adolescents with OCD [abstract]. Poster presented at the American Psychiatric Association (APA) Annual Meeting, Chicago, IL, May 13-18, 2000, Abstract No.NR556:208. (Study 453).
- Carpenter DJ, Hewett K, Duff D, et al. Are SSRI responders more likely to report discontinuation symptoms (DS)? Poster presented at New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting, Boca Raton, FL, June 2005. (Studies 676/701/704).
- Carpenter DJ, Kraus JE, Krulewicz S, Wilkinson C, Davies J. Meta-analysis of paroxetine efficacy in children and adolescents with MDD [abstract]. Presented at the New Clinical Drug Evaluation Unit (NCDEU) 47th Annual Meeting, Boca Raton, FL, June 2007, Abstract No.I-44. (Studies 329/377/701).
- Carpenter DJ, Kraus JE, Schaefer DM, et al. Incidence of abnormal bleeding with paroxetine use in children and adolescents [abstract]. Poster presented at the American Psychiatric Association (APA) Annual Meeting, San Diego, CA, May 19-24, 2007, Abstract No.3109. (Studies 329/377/701/676/704).
- Carpenter DJ, Lipschitz A, Fong R, et al. Is it appropriate to combine data from children and adolescents in pediatric MDD clinical trials?. Poster presented at New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting, Boca Raton, FL, June 2005. (Studies 329/377/701).

Carpenter DJ, Wetherhold E, Lipschitz A, et al. Adverse events emergent upon paroxetine discontinuation in children and adolescents. Poster presented at American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting, Washington DC, October 2004. (Studies 676/701/704).

Carrey N, Pharm AV. Suicidal ideation reports from pediatric trials for paroxetine and venlafaxine. *Can Child Adolesc Psychiatr Rev* 2003;12(4):101-102.

Cohen LG, Prince J, Doyle R, et al. Paroxetine for the treatment of depression in youth: a preliminary report [abstract]. *J Child Adolesc Psychopharmacol* 2002;12(4):298.

Correll CU, Pleak RR. Paroxetine in the treatment of adolescent major depression [letter to the editor]. *J Am Acad Child Adolesc Psychiatry* 2002;41:1269. (Study 329).

Dieleman GC, Ferdinand RF. Pharmacotherapy for social phobia, generalized anxiety disorder and separation anxiety disorder in children and adolescents: an overview. *Tijdschr Psychiatr* 2008;50(1):43-53.

Diler RS, Avci A. Open-label trial of paroxetine in children with obsessive-compulsive disorder. *Curr Ther Res Clin Exp* 2000;61:706-719.

Emslie GJ, Wagner KD, Kutcher S, et al. Paroxetine treatment in children and adolescents with major depressive disorder [abstract]. Abstract submitted to the American Academy of Children and Adolescent Psychiatry Annual Meeting, Washington, D.C., October 19-24, 2004. (Study 701).

Emslie GJ, Wagner KD, Kutcher S, et al. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry* 2006;45:709-719. (Study 701).

Emslie GJ, Wagner KD, Riddle MA, et al. Efficacy and safety of paroxetine in the treatment of children and adolescents with OCD. Poster presented at the American College of Neuropsychopharmacology (ACNP) Annual Meeting, Acapulco, Mexico, December, 1999. (Study 453).

Findling RL, Fong R, Carpenter DJ, et al. Multiple dose pharmacokinetics of paroxetine in children and adolescents. Poster presented at New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting, Boca Raton, FL, June 2005. (Study 715).

Findling RL, Fong R, Carpenter DJ, et al. Multiple dose pharmacokinetics of paroxetine in children and adolescents. Poster presented at the American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting, Toronto CA, October 2005. (Study 715).

Findling RL, Myers C, O'Riordan MA, et al. An open-label dosing study of paroxetine in depressed children and adolescents. *Cur Ther Res* 2002;63:588-600.

Findling RL, Nucci G, Piergies AA, et al. Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. *Neuropsychopharmacology* 2006;31:1274-1285. (Study 715).

Findling RL, Reed MD, Myers C, et al. Paroxetine pharmacokinetics in depressed children and adolescents. *J Am Acad Child Adolesc Psychiatry* 1999;38(8):952-959.

Fong R, Carpenter D, Lipschitz A, et al. Long term safety and tolerability of paroxetine in pediatric patients. Poster presented at the New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, June 6-9, 2005. (Study 716).

Fong R, Carpenter D, Lipschitz A, et al. Long-term safety and tolerability of paroxetine. *J Child Adolesc Psychopharmacol* 2005;15:856. (Study 716).

Fong R, Carpenter DJ, Lipschitz A, et al. Emergent and worsening suicide ideation in pediatric paroxetine depression trials [abstract]. Poster presented at American Psychiatric Association (APA) Annual Meeting, Atlanta, GA, May 21-26, 2005, Abstract No.NR591. (Studies 329/377/701).

Fong R, Lipschitz A, Carpenter DJ, et al. Suicidality in clinical trials: using multiple search strategies. Poster presented at the American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting, Washington DC, October 2004. (Studies 329/377/701).

Gagliano C. Paroxetine in adolescent depression. Poster presented at the World Congress of Psychiatry Meeting, Hamburg, Germany, August, 1999. (Study 329).

Gallagher D, Gardiner C, Carpenter DJ. Interim results of a 6-month extension study to assess the long term safety and tolerability of paroxetine in children and adolescents [abstract]. Poster presented at the American Psychiatric Association (APA) Annual Meeting, Philadelphia, PA, May 19-23, 2002, Abstract No.NR342. (Study 716).

Geller DA, Biederman J, Carpenter DJ, et al. Comorbid psychiatric illness and response to treatment in pediatric OCD [abstract]. Poster presented at the American Psychiatric Association (APA) Annual Meeting, New Orleans, LA, May 5-10, 2001, Abstract No. NR738:199. (Study 453).

Geller DA, Biederman J, Stewart SE, et al. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials. *J Child Adol Psychopharmacol* 2003;13(Suppl 1):S19-29. (Study 453).

Geller DA, Biederman J, Wagner KD, et al. Comorbid psychiatric illness and response to treatment, relapse rates, and behavioral adverse event incidence in pediatric OCD [abstract]. Poster presented at New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting, Phoenix, AZ, May 28-31, 2001, Abstract No.53. (Study 453).

Geller DA, Wagner KD, Emslie GJ, et al. Efficacy of paroxetine in pediatric OCD: results of a multicenter study. Poster presented at the American Academy of Children and Adolescent Psychiatry (AACAP) Annual Meeting, San Francisco, CA, October 22-27, 2002. (Study 704).

Geller DA, Wagner KD, Emslie GJ, et al. Efficacy of paroxetine in pediatric OCD: results of a multicenter study [abstract]. Poster presented at the American Psychiatric Association (APA) Annual Meeting, Philadelphia, PA, May 19-23, 2002, Abstract No.NR349:95. (Study 704).

Geller DA, Wagner KD, Emslie GJ, et al. Efficacy of paroxetine in pediatric OCD: results of a multicenter study [abstract]. Poster presented at the New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting, Boca Raton, FL, June, 2002, Abstract No.16. (Study 704).

Geller DA, Wagner KD, Emslie GJ, et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry* 2004;43(11):1387-1396. (Study 704).

Geller DA, Wagner KD, Emslie GJ. Efficacy and safety of paroxetine in pediatric OCD: results of a double-blind, placebo-controlled trial. *J Child Adolesc Psychopharmacol* 2002;12:299-300. (Study 704).

Gilbert AR, Maalouf FT. Pediatric obsessive-compulsive disorder: management in primary care. *Curr Opin Pediatr* 2008;20(5):544-550.

Gilbert AR, Maalouf FT. Pediatric obsessive-compulsive disorder: management in primary care. *Curr Opin Pediatr* 2008;5:544-550.

Greenhouse JB, Kaizar EE, Kelleher K, Seltman H, Gardner W. Generalizing from clinical trial data (a case study): the risk of suicidality among pediatric antidepressant users. *Stat Med* 2008;27(11):1801-1813.

Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. *Arch Gen Psychiatry* 2006;63:332-339. (Studies 329/377/676/701/704).

Hetrick S, Merry S, McKenzie J, Sindahl P, Proctor M. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. *Cochrane Libr* 2007;(3).

Holtkamp K, Herpertz-Dahlmann B. SSRI and SNRI treatment in children and adolescents: current views of the benefits and risks. *Nervenarzt* 2008;79(11):1237-1248.

Jick H, Kaye JA, Jick SS, et al. Antidepressants and the risk of suicidal behaviors. *JAMA* 2004;292:338-343.

Jureidini J, Tonkin A. Paroxetine in adolescent major depression [letter to the editor]. *J Am Acad Child Adolesc Psychiatry* 2003;42:514-515. (Study 329).

Jureidini JN, Doecke CJ, Mansfield PR, Haby MH, Menkes DB, Tonkin AL. Efficacy and safety of antidepressants for children and adolescents. *BMJ* 2004;328:879-883.

Kaakeh Y, Stumpf JL. Treatment of selective mutism: focus on selective serotonin reuptake inhibitors. *Pharmacotherapy* 2008;28(2):214-224.

Keller MB, Ryan ND, Birmaher B, et al. Efficacy of paroxetine in adolescent depression [abstract]. Poster presented at the American Psychiatric Association (APA) Annual Meeting, Toronto, Canada, May 30-June 4, 1998, Abstract No.NR206:123. (Study 329).

Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. *J Am Acad Child Adolesc Psychiatry* 2001;40(7):762-772. (Study 329).

Krulawicz S, Carpenter DJ, Fong R, et al. Analysis of electrocardiographic data following use of paroxetine in pediatric depression and obsessive-compulsive disorder. *J Am Acad Child Adolesc Psychiatry* 2006;45(4):422-430. (Studies 701/704/329).

Krulawicz S, Wagner KD, Carpenter DJ, et al. Electrocardiographic analysis of children and adolescents receiving paroxetine. Poster presented at the American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting, Miami, FL, October 14-19, 2003. (Studies 701/704/329).

Lee MS, Lee HY, Kim SH. Relapse of tic symptoms in a patient diagnosed with obsessive-compulsive disorder and treated with high-dose paroxetine. *J Child Adolesc Psychopharmacol* 2008;18(3):305-306.

Leo J. The SSRI trials in children: disturbing implications for academic medicine. *Eth Human Psychol Psychiatry* 2006;8(1):29-41.

Masi G, Toni C, Mucci M, et al. Paroxetine in child and adolescent outpatients with panic disorder. *J Child Adolesc Psychopharmacol* 2001;11:151-157.

McHenry LB, Jureidini JN. Industry-sponsored ghostwriting in clinical trial reporting: a case study. *Account Res* 2008;15(3):152-167.

Milin RP, Simeon J, Spent WP. Double-blind study of paroxetine in adolescents with unipolar major depression [abstract]. Poster presented at the Annual American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting, Chicago, IL, October 19-24, 1999, Abstract No.NR63:104-105. (Study 377).

Moreno C, Arango C, Parellada M, Shaffer D, Bird H. Antidepressants in child and adolescent depression: Where are the bugs? *Acta Psychiatr Scand*. 2007;115(3):184-195.

Nucci G, Fong R, Carpenter DJ, et al. Population pharmacokinetics of paroxetine in the pediatric population [abstract]. Abstract submitted and accepted but not presented at the Population Approach Group in Europe (PAGE) Annual Meeting, Pamplona Spain, June 2005, Abstract No.821. (Studies 676/701/704).

Oberlander TF, Grunau R, Mayes L, et al. Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure. *Early Hum Dev* 2008;84(10):689-697.

Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults a case-control study. *Arch Gen Psychiatry* 2006;63:865-872.

Palikova I, Zourkova A, Valentova D, Hadasova E, Ravcukova B. Mental bulimia and paroxetine treatment - monitoring CYP2D6 activity (preliminary results) [abstract]. *Eur Psychiatry* 2007;22:S179, Abstract No.P272.

Parsons M. Paroxetine in adolescent major depression [letter to the editor]. *J Am Acad Child Adolesc Psychiatry* 2002;41:364. (Study 329).

Prazeres AM, DeSouza WF, Fontenelle LF. Cognitive-behavior therapy for obsessive-compulsive disorder: a systematic review of the last decade. *Rev Bras Psiquiatr* 2007;29(3):262-270.

Reed MD, Findling RL, Capparelli EV, O'Riordan MA, Blumer JL. A population pharmacokinetic (POP-PK) model of steady-state (SS) paroxetine (PXT) in depressed children (C) and adolescents (A) [abstract]. *J Clin Pharmacol* 2003;43(9):1028, Abstract No.60.

Renaud J, Birmaher, Wassick SC, et al. Use of selective serotonin reuptake inhibitors for the treatment of childhood panic disorder. *J Child Adolesc Psychopharmacol* 1999;9:73-83.

Rey-Sánchez F, Gutiérrez-Casares J. Paroxetine in children with major depression disorder: an open trial. *J Am Acad Child Adolesc Psychiatry* 1997;36:1443-1447.

Rodríguez-Ramos P, de Dios-Vega JL, San-Sebastián-Cabases J, et al. Effects of paroxetine in depressed adolescents. *Eur J Clin Res* 1996;7:49-61.

Rosenberg DR, Stewart CM, Fitzgerald KD, et al. Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder. *J Am Acad Child Adolesc Psychiatry* 1999;38:1180-1185.

Sakolsky D, Birmaher B. Pediatric anxiety disorders: management in primary care. *Curr Opin Pediatr* 2008;20(5):538-543.

Santosh PJ, Suren R. Paediatric psychopharmacology - special considerations. *Psychiatry(GBR)* 2008;7(9):384-388.

Silveira R, Jainer AK, Singh R. Paroxetine in the treatment of adolescent major depression [letter to the editor]. *J Am Acad Child Adolesc Psychiatry* 2002;41:1270. (Study 329).

Storch EA, Merlo LJ, Larson MJ, et al. Clinical features associated with treatment-resistant pediatric obsessive-compulsive disorder. *Compr Psychiatry* 2008;49(1):35-42.

Vitiello B. Research in child and adolescent psychopharmacology: recent accomplishments and new challenges. *Psychopharmacology* 2007;191(1):5-13.

Wagner KD, Berard R, Stein MB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. *Arch Gen Psychiatry* 2004;61:1153-1162. (Study 676).

Wagner KD, Birmaher B, Carlson G, et al. Safety of paroxetine and imipramine in the treatment of adolescent depression. Poster presented at the New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting, Boca Raton, FL, 1998. (Study 329).

Wagner KD, Emslie GJ, Birmaher B, et al. Safety of paroxetine in the treatment of children and adolescents with OCD [abstract]. Poster presented at the New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, May 30-June 2, 2000, Abstract No.58. (Study 453).

Wagner KD, Stein MB, Berard R, et al. Efficacy of paroxetine in childhood and adolescent social anxiety disorder. Poster presented at the American Academy of Children and Adolescent Psychiatry (AACAP) Annual Meeting, San Francisco, CA, October 22-27, 2002. (Study 676).

Wagner KD, Stein MB, Berard R, et al. Efficacy of paroxetine in childhood and adolescent social anxiety disorder. Poster presented at the American College of Neuropsychopharmacology (ACNP) Annual Meeting, San Juan, PR, December 8-12, 2002. (Study 676).

Wagner KD, Wetherhold E, Carpenter DJ, et al. Safety and tolerability of paroxetine in children and adolescents: pooled results from five multicenter, placebo-controlled trials [abstract]. Abstract submitted and accepted but not presented at the American Academy of Children and Adolescent Psychiatry (AACAP) Annual Meeting, San Francisco, CA, October 22-27, 2002. (Studies 329/377/701/704/676).

Wagner KD, Wetherhold E, Carpenter DJ, et al. Safety and tolerability of paroxetine in children and adolescents: pooled results from four multicenter, placebo-controlled trials. *J Child Adolesc Psychopharmacol* 2002;12:297-298.

Wagner KD, Wetherhold E, Carpenter DJ, et al. Safety and tolerability of paroxetine in children and adolescents: pooled results from four multicenter, placebo-controlled trials [abstract]. Poster presented at the New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, June, 2002, Abstract No.61. (Studies 329/377/701/704)

Wagner KD, Wetherhold E, Gee M, et al. Remission of pediatric social anxiety disorder with paroxetine [abstract]. Poster presented at the American Psychiatric Association (APA) Annual Meeting, San Francisco, CA, May 17-22, 2003, Abstract No.NR701. (Study 676).

Wagner KD, Wetherhold E, Gee M, et al. Remission of pediatric social anxiety disorder with paroxetine [abstract]. Poster presented at the New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, May, 2003, Abstract No.56. (Study 676).

Wagner KD. Paroxetine treatment of mood and anxiety disorders in children and adolescents. *Psychopharmacol Bull* 2003;37(Suppl 1):167-175.

Weintrob A. Paroxetine in adolescent major depression [letter to the editor]. *J Am Acad Child Adolesc Psychiatry* 2002;41:363-364. (Study 329).

Wetherhold E, Carpenter DJ, Fong R, et al. Long-term safety and tolerability of paroxetine in pediatric patients [abstract]. Abstract submitted (not accepted) to the American Academy of Children and Adolescent Psychiatry Annual Meeting, Washington, DC, Oct 19-24, 2004. (Study 716).

Wetherhold E, Carpenter DJ, Lipschitz A, et al. Safety and tolerability of paroxetine in pediatric patients [abstract]. Abstract submitted to the American Academy of Children and Adolescent Psychiatry Annual Meeting, Washington, DC, Oct 19-24, 2004. (Studies 329/377/701/704/676)

Wetherhold E, Wagner KD, Carpenter DJ, et al. Paroxetine improves school performance measures in children and adolescents with social anxiety disorder: a retrospective analysis. Poster presented at the American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting, Miami, FL, October 14-19, 2003. (Study 676).